Longevity science

Earlier this year, a team from UC San Francisco reported on the discovery that a class of commonly prescribed type-2 diabetes drugs, called TZDs (thiazolidinediones, such as Actos and Avandia), promoted the conversion of energy-storing white fat cells into energy-burning brown fat cells. Now researchers at Columbia University Medical Center (CUMC) have identified the mechanism that causes this change to take place, potentially leading to new treatments for obesity and type-2 diabetes.

While it was known that TZDs have the ability to change white fat cells to brown fat cells by activating a cell receptor called peroxisome proliferator-activated receptor–gamma (ppar-gamma), the exact mechanism behind this transformation was unclear. Because TZDs have numerous adverse side effects,

Researchers from Purdue University in Indiana are testing a compound found in red wine that has the ability to block the processes of fat cell development. The research into the compound known as piceatannol may lead towards finding a simple method to combat obesity.

Piceatannol results from the conversion of resveratrol – a compound found in red wine, grapes and peanuts that is also thought to combat cancer, heart disease and neurodegenerative diseases. When resveratrol is converted into the piceatannol